Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05160571 · ClinicalTrials.gov registry record
A Retrospective Multicenter Review to Evaluate the Performance of the Ion Endoluminal System in Sampling Pulmonary Lesions
A clinical trial of Lung Cancer and Pulmonary Nodule, sponsored by Intuitive Surgical.
- Completed
- Registry status
- 279
- Enrollment target
- 1
- Study location
NCT05160571: Completed study of Lung Cancer and Pulmonary Nodule, sponsored by Intuitive Surgical.
NCT05160571 is a study of Lung Cancer and Pulmonary Nodule that has completed, run by Intuitive Surgical. The registered enrollment target is 279 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05160571, a study of Lung Cancer and Pulmonary Nodule, has completed, sponsored by Intuitive Surgical.
- COMPLETED
- Registry status
- 279 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a retrospective multi-center chart review of patients who underwent an attempted biopsy of one or more pulmonary lesion(s) with the Ion Endoluminal System with the aim of assessing the overall performance of the system.
Primary Outcome
Diagnostic yield of the sample obtained through the bronchoscopy procedure, with diagnostic yield defined as (true positives + true negatives)/(total number of lesions biopsied)
Conditions Studied
Interventions
- DEVICE Ion Endoluminal System
Study Locations (1)
Virginia
- Winchester Medical Center - Winchester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2022-12-31 |
What the finished NCT05160571 record still lists
NCT05160571 is an observational study that tracks outcomes without assigning an intervention. The registered 279 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ion Endoluminal System is the first listed.
NCT05160571 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT05160571 about?
NCT05160571 is a clinical study titled "A Retrospective Multicenter Review to Evaluate the Performance of the Ion Endoluminal System in Sampling Pulmonary Lesions". This study is a retrospective multi-center chart review of patients who underwent an attempted biopsy of one or more pulmonary lesion(s) with the Ion Endoluminal System with the aim of assessing the overall performance of the system.
What is the current status of trial NCT05160571?
This trial is currently completed. The enrollment target is 279 participants. The study started on 2021-11-01. Estimated completion is 2022-12-31.
What conditions does trial NCT05160571 study?
This clinical trial studies the following conditions: Lung Cancer, Pulmonary Nodule.
What interventions are being tested in trial NCT05160571?
The interventions under investigation include: Ion Endoluminal System (DEVICE).
Who is sponsoring clinical trial NCT05160571?
This trial is sponsored by Intuitive Surgical, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05160571 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05160571's enrollment target sits among peer trials
279 107th of 409 higher than 302 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04783857 · 279 participants · Phase 4
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
- NCT05407324 · 279 participants · Phase 2
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
- NCT06299748 · 279 participants
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
- NCT06582784 · 279 participants · NA
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI